[1] |
KE Xiuqin, HAI Xuewu.
433 Cases of Adverse Drug Reactions Induced by Calcium Dobesilate Capsules
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 924-927.
|
[2] |
ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing.
Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
|
[3] |
ZHENG Sili, ZHANG Xiaoqing.
133 Cases of Adverse Drug Reactions in Female Patients
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 654-658.
|
[4] |
WANG Hao, MA Jinfu, MA Rui, LI Xiaogang, ZHAO Qiang, ZHANG Xian.
One Case of Thrombocytopenia Caused by Cefoperazone Sulbactam Sodium for Injection
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 686-688.
|
[5] |
MEI Liping, BAI Fuchen, YU Jie, ZHANG Chunjie, WANG Yajun, AN Limei.
Determinants of Blood Drug Concentration / Dose Ratio of Antipsychotics
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 424-428.
|
[6] |
ZOU Yuanlei, XIA Qingrong, LIANG Jun, HE Kongliang, MO Daming, WU Wenning.
Words of Warning and Preventive Measures in Labels of Antidepressants
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 329-333.
|
[7] |
ZHOU Kun, MA Liang, LI Zhaofeng, CAO Bing, GU Hongwei, LIU Qian.
Usage of Nerve-Calming Chinese Herbal Patent Medicines in a Mental Health Center
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 211-216.
|
[8] |
NIE Xiaolu, SUN Feng, YAN Aixia, PENG Xiaoxia, ZHAN Siyan.
Methodology for Constructing Benchmark Database of Adverse Drug Reactions Based on Multi-Source Information
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 10-15.
|
[9] |
ZHANG Caixia, ZHOU Yi, TAN Lu, CHEN Wenming, LIU Yang, YOU Yu.
Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1064-1067.
|
[10] |
YAN Yan, LIU Naiyi, QIAO Ling, ZHANG Yi, YANG Chen.
One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1068-1070.
|
[11] |
ALATENG Hua, WANG Zhenxing, ZHANG Xiaomeng, SHI Wei, XI Chengwei, WANG Conghui, WANG Liqun, ZHANG Bing.
Mining and analysis of cardiac disorders risk signals based on adverse drug reaction monitoring data
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 752-758.
|
[12] |
ZHAO Xuan, ZHENG Tingting, LI Xuemei, MAO Lu, GUO Jing, ZHANG Wei.
Adverse reaction reports of vancomycin in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 811-815.
|
[13] |
SUN Xuelin, DU Jiao, TAN Qin, HU Xin, ZHANG Yatong, ZHENG Li.
Analysis of post-marketing adverse reactions of ametinib
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 683-686.
|
[14] |
LIN Yanxin, LIU Yanhui, DONG Jing, YAO Jiachen, LI Wenyan.
Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 693-696.
|
[15] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|